Duchenne News

November 7, 2024
On November 6, 2024, reported financial results and recent operational highlights for the third quarter ended September 30, 2024. Please continue reading to view their full press release. ROCKVILLE, Md., Nov....
November 7, 2024
Business updates, third quarter financial results, and a letter to the Duchenne community.
November 7, 2024
A full update on Sarepta's decision to discontinue development of SRP-5051.
October 30, 2024
PTC Therapeutics announced the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application for Translarna™.
September 4, 2024
On September 4, 2024, PepGen shared their mid year advocacy newsletter with updates from Q2 and Q3. Please click here to view their newsletter.
August 14, 2024
On August 13, 2024, Solid Biosciences reported financial results for the second quarter ended June 30, 2024, and provided a business update. Please continue reading to view their press release. To...
August 9, 2024
Avidity shares updates on EXPLORE44 trial in a community letter and press release.
August 6, 2024
Data updates for Phase I/II AFFINITY DUCHENNE® trial of RGX-202.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open